Obesity And Weight Management Market Progress In Q3 2025

The obesity and weight management space remained highly active during Q3 2025, with key players focusing on clinical innovation, patient engagement, and access support. A large majority of the materials were aimed at healthcare professionals, with an equal number distributed through digital channels and traditional print formats.

Currax broadened its national presence through the “Cravings Don’t Own Me” CTV ad and the “Real Patients, Real Results” campaign, featuring patient testimonials alongside Contrave data on fat mass reduction, cost-saving options, and resources to support provider conversations.

Lilly announced positive Phase 3 results for orforglipron.

Vivus positioned Qsymia as a non-injection option, promoting meaningful weight loss, blood pressure benefits, and multiple savings programs.

As part of the “Power of Wegovy” campaign, materials emphasized Wegovy’s dual impact on weight loss and cardiovascular risk reduction, backed by clinical and real-world evidence.

Lilly promoted Zepbound for obesity with moderate-to-severe OSA, backed by SURMOUNT-1 data and tools like LillyTap, BMI charts, and Thrive AI Health access.